Trial Outcomes & Findings for CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia (NCT NCT04860830)
NCT ID: NCT04860830
Last Updated: 2026-02-06
Results Overview
The MCCB assesses 7 cognitive domains, including speed of processing, attention vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. T-scores in the general population have a mean of 50 and standard deviation of 10, and a higher score indicates better cognition. The primary analysis was a restricted maximum likelihood (REML) based approach using a mixed-effects model for repeated measurements (MMRM), which included the fixed categorical effects of treatment at each visit, fixed categorical effect of the stratification factor using the screening MCCB overall composite T-score, and a fixed effect for the continuous covariate of baseline at each visit. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-subject dependencies. Intercurrent events were addressed using different pre-defined strategies.
COMPLETED
PHASE3
609 participants
The MMRM model incorporates values from baseline (Week 0), Week 12 and Week 26. The data represent the Least Squares Means at Week 26.
2026-02-06
Participant Flow
Multi-center, multi-national, randomized, double-blind, placebo controlled, parallel group, 26-week trial in patients with schizophrenia on stable antipsychotic treatment randomized with equal ratio to iclepertin or placebo. Patients who completed the trial could directly enroll into a open-label extension trial to assess the long-term safety and tolerability of iclepertin (1346-0014). A dedicated ocular sub-study was conducted in several countries to investigate the ocular safety of iclepertin.
Patients and study partners signed informed consent forms and were informed that they were free to withdraw consent at any time without penalty or prejudice. All patients were screened for eligibility prior to participation and attended a specialist site which ensured that they strictly met all inclusion and no exclusion criteria. Study partners were not enrolled nor assigned a study ID, and other than the endpoints related to patients, no other data was collected from them.
Participant milestones
| Measure |
Iclepertin 10 mg
Patients with schizophrenia took one tablet of 10 milligram (mg) iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
Placebo
Patients with schizophrenia took one tablet of placebo matching iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
|---|---|---|
|
Overall Study
STARTED
|
303
|
306
|
|
Overall Study
Treated
|
301
|
305
|
|
Overall Study
Ocular safety sub-study
|
36
|
38
|
|
Overall Study
COMPLETED
|
271
|
258
|
|
Overall Study
NOT COMPLETED
|
32
|
48
|
Reasons for withdrawal
| Measure |
Iclepertin 10 mg
Patients with schizophrenia took one tablet of 10 milligram (mg) iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
Placebo
Patients with schizophrenia took one tablet of placebo matching iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
|---|---|---|
|
Overall Study
Adverse Event
|
8
|
18
|
|
Overall Study
Perceived lack of efficacy
|
1
|
6
|
|
Overall Study
Change of residence
|
4
|
2
|
|
Overall Study
Burden of study procedures
|
2
|
4
|
|
Overall Study
No reason available
|
3
|
2
|
|
Overall Study
Subject decision
|
9
|
12
|
|
Overall Study
Physician Decision
|
1
|
0
|
|
Overall Study
Other than listed
|
2
|
3
|
|
Overall Study
Not treated
|
1
|
0
|
|
Overall Study
Randomized in error and not treated
|
1
|
1
|
Baseline Characteristics
CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia
Baseline characteristics by cohort
| Measure |
Iclepertin 10 mg
n=302 Participants
Patients with schizophrenia took one tablet of 10 milligram (mg) iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
Placebo
n=305 Participants
Patients with schizophrenia took one tablet of placebo matching iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
Total
n=607 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
34.3 Years
STANDARD_DEVIATION 8.7 • n=41 Participants
|
33.4 Years
STANDARD_DEVIATION 8.8 • n=1581 Participants
|
33.8 Years
STANDARD_DEVIATION 8.8 • n=4626 Participants
|
|
Sex: Female, Male
Female
|
94 Participants
n=41 Participants
|
130 Participants
n=1581 Participants
|
224 Participants
n=4626 Participants
|
|
Sex: Female, Male
Male
|
208 Participants
n=41 Participants
|
175 Participants
n=1581 Participants
|
383 Participants
n=4626 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
71 Participants
n=41 Participants
|
83 Participants
n=1581 Participants
|
154 Participants
n=4626 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
231 Participants
n=41 Participants
|
222 Participants
n=1581 Participants
|
453 Participants
n=4626 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=41 Participants
|
0 Participants
n=1581 Participants
|
0 Participants
n=4626 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
10 Participants
n=41 Participants
|
7 Participants
n=1581 Participants
|
17 Participants
n=4626 Participants
|
|
Race (NIH/OMB)
Asian
|
112 Participants
n=41 Participants
|
116 Participants
n=1581 Participants
|
228 Participants
n=4626 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
1 Participants
n=41 Participants
|
0 Participants
n=1581 Participants
|
1 Participants
n=4626 Participants
|
|
Race (NIH/OMB)
Black or African American
|
27 Participants
n=41 Participants
|
24 Participants
n=1581 Participants
|
51 Participants
n=4626 Participants
|
|
Race (NIH/OMB)
White
|
149 Participants
n=41 Participants
|
155 Participants
n=1581 Participants
|
304 Participants
n=4626 Participants
|
|
Race (NIH/OMB)
More than one race
|
3 Participants
n=41 Participants
|
3 Participants
n=1581 Participants
|
6 Participants
n=4626 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=41 Participants
|
0 Participants
n=1581 Participants
|
0 Participants
n=4626 Participants
|
|
Overall composite T-score of the MATRICS consensus cognitive battery (MCCB)
|
29.4 T-score
STANDARD_DEVIATION 14.1 • n=41 Participants
|
29.8 T-score
STANDARD_DEVIATION 13.5 • n=1581 Participants
|
29.6 T-score
STANDARD_DEVIATION 13.8 • n=4626 Participants
|
PRIMARY outcome
Timeframe: The MMRM model incorporates values from baseline (Week 0), Week 12 and Week 26. The data represent the Least Squares Means at Week 26.Population: Randomized Set (RS): all patients who signed informed consent and were randomized into the trial, regardless of whether they were treated with trial medication. Patients randomized in error and discontinued from the study before the start of trial medication were excluded from the RS.
The MCCB assesses 7 cognitive domains, including speed of processing, attention vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. T-scores in the general population have a mean of 50 and standard deviation of 10, and a higher score indicates better cognition. The primary analysis was a restricted maximum likelihood (REML) based approach using a mixed-effects model for repeated measurements (MMRM), which included the fixed categorical effects of treatment at each visit, fixed categorical effect of the stratification factor using the screening MCCB overall composite T-score, and a fixed effect for the continuous covariate of baseline at each visit. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-subject dependencies. Intercurrent events were addressed using different pre-defined strategies.
Outcome measures
| Measure |
Iclepertin 10 mg
n=302 Participants
Patients with schizophrenia took one tablet of 10 milligram (mg) iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
Placebo
n=305 Participants
Patients with schizophrenia took one tablet of placebo matching iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
|---|---|---|
|
Change From Baseline in Overall Composite T-score of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) After 26 Weeks of Treatment
|
1.890 T-score
Standard Error 0.3336
|
2.273 T-score
Standard Error 0.3372
|
SECONDARY outcome
Timeframe: The MMRM model incorporates values from baseline (Week 0), Week 12 and Week 26. The data represent the Least Squares Means at Week 26.Population: Randomized Set (RS): all patients who signed informed consent and were randomized into the trial, regardless of whether they were treated with trial medication. Patients randomized in error and discontinued from the study before the start of trial medication were excluded from the RS.
SCoRS is a 20-item interview-based assessment of cognitive deficits and the degree to which they affect day-to-day functioning. Each item is rated on a 4-point scale. Higher ratings reflect a greater degree of impairment. The interviewer integrates information from separate patient and study partner interviews to generate a total score, which ranges from 20 to 80. The analysis was a REML-based approach using a MMRM model, which included the discrete fixed effects of treatment at each visit, fixed categorical covariate of the stratification factor using the screening MCCB overall composite T-score, a fixed effect for the continuous covariate of baseline at each visit. Visit was treated as the repeated measure with an unstructured covariance structure to model the within-subject measurements. Subjects were considered as a random effect. Intercurrent events were addressed using different pre-defined strategies.
Outcome measures
| Measure |
Iclepertin 10 mg
n=302 Participants
Patients with schizophrenia took one tablet of 10 milligram (mg) iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
Placebo
n=305 Participants
Patients with schizophrenia took one tablet of placebo matching iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
|---|---|---|
|
Change From Baseline in the Schizophrenia Cognition Rating Scale (SCoRS) Interviewer Total Score After 26 Weeks of Treatment
|
-3.751 Scores on a scale
Standard Error 0.3697
|
-4.513 Scores on a scale
Standard Error 0.3728
|
SECONDARY outcome
Timeframe: The MMRM model incorporates values from baseline (Week 0), Week 12 and Week 26. The data represent the Least Squares Means at Week 26.Population: Randomized Set (RS): all patients who signed informed consent and were randomized into the trial, regardless of whether they were treated with trial medication. Patients randomized in error and discontinued from the study before the start of trial medication were excluded from the RS.
The VRFCAT is a virtual reality shopping trip performed on a tablet, and was used as an electronic Functional Capacity measure by measuring the total time adjusting for the number of errors. T-scores in the general population have a mean of 50 and standard deviation of 10, and a higher score indicates a better functional outcome. The analysis was a REML-based approach using a MMRM model, which included the discrete fixed effects of treatment at each visit, fixed categorical covariate of the stratification factor using the screening MCCB overall composite T-score, a fixed effect for the continuous covariate of baseline at each visit. Visit was treated as the repeated measure with an unstructured covariance structure to model the within-subject measurements. Subjects were considered as a random effect. Intercurrent events were addressed using different pre-defined strategies.
Outcome measures
| Measure |
Iclepertin 10 mg
n=302 Participants
Patients with schizophrenia took one tablet of 10 milligram (mg) iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
Placebo
n=305 Participants
Patients with schizophrenia took one tablet of placebo matching iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
|---|---|---|
|
Change From Baseline to Week 26 in the Adjusted Total Time T-score in Virtual Reality Functional Capacity Assessment Tool (VRFCAT)
|
1.820 T-score
Standard Error 0.7633
|
3.042 T-score
Standard Error 0.7669
|
SECONDARY outcome
Timeframe: At baseline (Week 0) and at Week 26.Population: Randomized Set (RS): all patients who signed informed consent and were randomized into the trial, regardless of whether they were treated with trial medication. Patients randomized in error and discontinued from the study before the start of trial medication were excluded from the RS. Only patients with available data at Week 26 were included in the analysis.
This is an Executive Functions/Reasoning and Problem Solving test where patients were shown two images on opposite sides of a tablet screen. Each image showed a different configuration of 3 colored balls arranged on 3 pegs. Patients were required to accurately determine the total number of times the balls in one picture would have to be moved in order to make the arrangement of balls identical to that of the other opposing picture, while employing the standard rules employed in tower tests. T-scores in the general population have a mean of 50 and standard deviation of 10, and a higher score indicates a better outcome. The analysis was performed with an analysis of covariance (ANCOVA) model, which included treatment, stratification factor of screening MCCB overall composite T-score (\< 30, ≥ 30), and baseline number of correct responses on Tower of London T-score.
Outcome measures
| Measure |
Iclepertin 10 mg
n=280 Participants
Patients with schizophrenia took one tablet of 10 milligram (mg) iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
Placebo
n=277 Participants
Patients with schizophrenia took one tablet of placebo matching iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
|---|---|---|
|
Change From Baseline to Week 26 in the T-score of the Number of Correct Responses on Tower of London
|
0.440 T-score
Standard Error 0.5773
|
1.016 T-score
Standard Error 0.5805
|
SECONDARY outcome
Timeframe: The MMRM model incorporates values from baseline (screening), Week 15 and Week 24. The data represent the Least Squares Means at Week 24.Population: Randomized Set (RS): all patients who signed informed consent and were randomized into the trial, regardless of whether they were treated with trial medication. Patients randomized in error and discontinued from the study before the start of trial medication were excluded from the RS.
PRECIS consists of 26 items covering 6 domains (memory, communication, self-control, executive function, attention, and sharp thinking), and 2 additional items assessing the overall degree of bother associated with all domains. Questions are answered via a 5-category Likert scale, with higher scores indicating a worse patient experience. The total score, ranging from 26 to 130, is the average score of the first 26 items. The analysis was a REML-based approach using a MMRM model, which included the discrete fixed effects of treatment at each visit, fixed categorical covariate of the stratification factor using the screening MCCB overall composite T-score, and continuous fixed effects for the corresponding baseline endpoint value at each visit. Visit was treated as the repeated measure with an unstructured covariance structure to model the within-subject measurements. Subjects were considered as a random effect. Intercurrent events were addressed using different pre-defined strategies.
Outcome measures
| Measure |
Iclepertin 10 mg
n=302 Participants
Patients with schizophrenia took one tablet of 10 milligram (mg) iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
Placebo
n=305 Participants
Patients with schizophrenia took one tablet of placebo matching iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
|---|---|---|
|
Change From Screening Visit 1a to Week 24 in Patient Reported Experience of Cognitive Impairment in Schizophrenia (PRECIS) Total Score
|
-0.275 Scores on a scale
Standard Error 0.0274
|
-0.234 Scores on a scale
Standard Error 0.0278
|
SECONDARY outcome
Timeframe: Measurements were performed at baseline (screening) and at Week 24.Population: Ocular sub-study Set (EYE): all treated patients who consented to participate in the ocular sub-study (including late/retrospective consent to the ocular sub-study) and had evaluable ophthalmologic measurements.
The Humphrey visual field is a diagnostic test to measure visual fields, or perimetry. The Humphrey visual field test measures the entire area of peripheral vision that can be seen while the eye is focused on a central point. During this test, lights of varying intensities appear in different parts of the visual field while the patient's eye is focused on a central spot. The perception of these lights is charted and then compared to results of a healthy eye at the same age of the patient to determine if any damage has occurred. Visual field Index goes from 100%= perfect to 0= no vision.
Outcome measures
| Measure |
Iclepertin 10 mg
n=26 Participants
Patients with schizophrenia took one tablet of 10 milligram (mg) iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
Placebo
n=32 Participants
Patients with schizophrenia took one tablet of placebo matching iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
|---|---|---|
|
Ocular Safety Sub-study: Change From Baseline in Humphrey Visual Field 24-2 Swedish Interactive Thresholding Algorithm (SITA) Standard at Week 24
Left eye
|
2.00 Units on a scale
Standard Deviation 6.06
|
-3.97 Units on a scale
Standard Deviation 12.99
|
|
Ocular Safety Sub-study: Change From Baseline in Humphrey Visual Field 24-2 Swedish Interactive Thresholding Algorithm (SITA) Standard at Week 24
Right eye
|
-0.31 Units on a scale
Standard Deviation 3.56
|
-4.44 Units on a scale
Standard Deviation 15.51
|
SECONDARY outcome
Timeframe: Measurements were performed at baseline (screening) and at Week 24.Population: Ocular sub-study Set (EYE): all treated patients who consented to participate in the ocular sub-study (including late/retrospective consent to the ocular sub-study) and had evaluable ophthalmologic measurements.
The central retinal thickness measurements were recorded for each eye via high definition optical coherence tomography (spectral domain OCT) to evaluate the retinal and sub-retinal structures.
Outcome measures
| Measure |
Iclepertin 10 mg
n=28 Participants
Patients with schizophrenia took one tablet of 10 milligram (mg) iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
Placebo
n=32 Participants
Patients with schizophrenia took one tablet of placebo matching iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
|---|---|---|
|
Ocular Safety Sub-study: Change From Baseline in Spectral Domain Ocular Coherence Tomography (OCT)
Left eye
|
-1.57 Micrometer (µm)
Standard Deviation 7.25
|
-1.47 Micrometer (µm)
Standard Deviation 10.08
|
|
Ocular Safety Sub-study: Change From Baseline in Spectral Domain Ocular Coherence Tomography (OCT)
Right eye
|
-1.14 Micrometer (µm)
Standard Deviation 5.70
|
-2.41 Micrometer (µm)
Standard Deviation 11.75
|
Adverse Events
Iclepertin 10 mg
Placebo
Serious adverse events
| Measure |
Iclepertin 10 mg
n=301 participants at risk
Patients with schizophrenia took one tablet of 10 milligram (mg) iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
Placebo
n=305 participants at risk
Patients with schizophrenia took one tablet of placebo matching iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
|---|---|---|
|
Eye disorders
Central serous chorioretinopathy
|
0.33%
1/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
0.00%
0/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
|
Eye disorders
Ulcerative keratitis
|
0.33%
1/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
0.00%
0/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
|
Gastrointestinal disorders
Pancreatitis acute
|
0.33%
1/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
0.00%
0/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
|
Hepatobiliary disorders
Cholecystitis acute
|
0.00%
0/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
0.33%
1/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
|
Infections and infestations
Bronchiolitis
|
0.33%
1/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
0.00%
0/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
0.33%
1/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
|
Infections and infestations
COVID-19
|
0.33%
1/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
0.00%
0/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
|
Infections and infestations
Gastroenteritis
|
0.33%
1/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
0.00%
0/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
|
Injury, poisoning and procedural complications
Limb crushing injury
|
0.00%
0/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
0.33%
1/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
|
Psychiatric disorders
Schizophrenia
|
1.00%
3/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
0.66%
2/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
|
Psychiatric disorders
Suicidal behaviour
|
0.00%
0/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
0.66%
2/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
|
Psychiatric disorders
Suicidal ideation
|
1.00%
3/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
2.0%
6/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
|
Psychiatric disorders
Suicide attempt
|
0.00%
0/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
0.33%
1/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
|
Renal and urinary disorders
Hydronephrosis
|
0.00%
0/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
0.33%
1/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.33%
1/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
0.00%
0/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
0.33%
1/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal septum deviation
|
0.33%
1/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
0.00%
0/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
|
Skin and subcutaneous tissue disorders
Eczema
|
0.33%
1/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
0.00%
0/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
Other adverse events
| Measure |
Iclepertin 10 mg
n=301 participants at risk
Patients with schizophrenia took one tablet of 10 milligram (mg) iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
Placebo
n=305 participants at risk
Patients with schizophrenia took one tablet of placebo matching iclepertin orally once daily for 26 weeks. Patients were permitted to remain on other antipsychotic and psychotropic medications, as specified in the eligibility criteria.
|
|---|---|---|
|
Infections and infestations
Nasopharyngitis
|
5.6%
17/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
6.2%
19/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
|
Investigations
Weight increased
|
3.7%
11/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
6.6%
20/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
|
Nervous system disorders
Headache
|
9.3%
28/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
7.2%
22/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
|
Psychiatric disorders
Schizophrenia
|
6.6%
20/301 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
3.6%
11/305 • From first treatment administration until last treatment administration plus residual effect period, up to approximately 31 weeks.
Treated Set (TS): includes all patients who signed informed consent and were treated with at least one dose of the trial medication. Study partners were not assessed or monitored for deaths and adverse events.
|
Additional Information
Boehringer Ingelheim, Call Center
Boehringer Ingelheim
Results disclosure agreements
- Principal investigator is a sponsor employee Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.
- Publication restrictions are in place
Restriction type: OTHER